CoChat
Sign Up
Cited by 16MicroRNA in disease regulationCancer-related molecular mechanisms researchHead and Neck Cancer Studies

miR-23a-3p Regulates Runx2 to Inhibit the Proliferation and Metastasis of Oral Squamous Cell Carcinoma

Open access
Ma, Yu, Gao, Jinbo, Guo, Hongning·2022·Journal of Oncology
DOI 10.1155/2022/8719542PMC PMC8956426
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: To investigate the effects of microRNA-23a (miR-23a-3p) and Runx2 on malignant progression of oral cancer cells and their possible molecular mechanisms. Methods: Fluorescence quantitative PCR (qPCR) was used to detect the expression of miR-23a-3p and Runx2 in human oral squamous cell carcinoma tissues and paracancerous tissues. The dual luciferase reporter assay was used to evaluate the targeted regulation of miR-23a-3p on Runx2. A subcutaneous xenograft model was established to investigate the tumor-suppressive effect of miR-23a-3p. Cells were transfected with miR-23a-3p mimics and negative control NC. CCK-8 assay, EDU assay, Transwell assay, and clone formation assay were used to detect malignant evolution of cells. Western blotting was used to detect the expression of Runx2, PTEN, and PI3K/Akt. The cells were simultaneously transfected with miR-23a-3p mimics and Runx2 to detect the malignant evolution of cells. Results: The expression of miR-23a-3p was downregulated in oral squamous cell carcinoma tissues, while the expression of Runx2 was upregulated. Overexpression of miR-23a-3p or inhibition of Runx2 inhibited the malignant progression of oral squamous cell carcinoma CAL-27 and TSCCA. Overexpression of miR-23a-3p inhibits the growth of oral cancer tumors. miR-23a-3p inhibits the PTEN/PI3K/Akt signaling pathway through Runx2. Overexpression of Runx2 reverses the tumor-suppressive effect of miR-23a-3p. Conclusion: miR-23a-3p can inhibit the PI3K/Akt signaling pathway by targeting Runx2 and inhibit the malignant evolution of oral cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2022/8719542

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-23a-3p is downregulated in oral squamous cell carcinoma tissue.

    “The miR-23a-3p is downregulated in oral squamous cell carcinoma (OSCC) tissue”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [81]

  • Overexpression of miR-23a-3p inhibits the PTEN/PI3K/Akt signaling pathway by suppressing Runx2, curbing proliferation and metastasis of OSCC.

    “its overexpression can inhibit the PTEN/PI3K/Akt signaling pathway by suppressing the target gene Runx2, thereby curbing the proliferation and metastasis of OSCC [81].”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [81]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 30 · Cited by 16

Research works printed but not linked: 30

  1. [1]Markopoulos A. K. Current aspects on oral squamous cell carcinoma The Open Dentistry Journal 2012 6 1 126 130 10.2174/1874210601206010126 2-s2.0-84871034926 22930665 PMC3428647 · DOI
  2. [2]Rivera C. Venegas B. Histological and molecular aspects of oral squamous cell carcinoma (review) Oncology Letters 2014 8 1 7 11 10.3892/ol.2014.2103 2-s2.0-84901235647 24959211 PMC4063640 · DOI
  3. [3]Sun Z. Shi K. Yang S. Effect of exosomal miRNA on cancer biology and clinical applications Molecular Cancer 2018 17 1 1 19 10.1186/s12943-018-0897-7 2-s2.0-85054746556 30309355 PMC6182840 · DOI · Paper page
  4. [4]Liu X. Edinger R. S. Klemens C. A. A microRNA cluster miR-23–24–27 is upregulated by aldosterone in the distal kidney nephron where it alters sodium transport Journal of Cellular Physiology 2017 232 6 1306 1317 10.1002/jcp.25599 2-s2.0-85008147383 27636893 PMC5426511 · DOI
  5. [5]He Y. Meng C. Shao Z. Wang H. Yang S. MiR-23a functions as a tumor suppressor in osteosarcoma Cellular Physiology and Biochemistry 2014 34 5 1485 1496 10.1159/000366353 2-s2.0-84908292868 25322765 · DOI · Paper page
  6. [6]Liu P. Wang C. Ma C. Wu Q. Zhang W. Lao G. MicroRNA-23a regulates epithelial-to-mesenchymal transition in endometrial endometrioid adenocarcinoma by targeting SMAD3 Cancer Cell International 2016 16 1 1 9 10.1186/s12935-016-0342-1 2-s2.0-84985028293 27601936 PMC5011925 · DOI
  7. [7]Zhu L. H. Liu T. Tang H. MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor The FEBS Journal 2010 277 18 3726 3734 10.1111/j.1742-4658.2010.07773.x 2-s2.0-77956311739 20698883 · DOI
  8. [8]Liu X. Liu Q. Fan Y. Downregulation of PPP2R5E expression by miR-23a suppresses apoptosis to facilitate the growth of gastric cancer cells FEBS Letters 2014 588 17 3160 3169 10.1016/j.febslet.2014.05.068 2-s2.0-84906250463 24997345 · DOI
  9. [9]Voon D. C. C. Hor Y. T. Ito Y. The RUNX complex: reaching beyond haematopoiesis into immunity Immunology 2015 146 4 523 536 10.1111/imm.12535 2-s2.0-84983200707 26399680 PMC4693896 · DOI
  10. [10]Chuang L. S. H. Ito K. Ito Y. RUNX family: regulation and diversification of roles through interacting proteins International Journal of Cancer 2013 132 6 1260 1271 10.1002/ijc.27964 2-s2.0-84872980046 23180629 · DOI
  11. [11]Fijneman R. J. Anderson R. A. Richards E. Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract Cancer Science 2012 103 3 593 599 10.1111/j.1349-7006.2011.02189.x 2-s2.0-84859705566 22171576 PMC5439111 · DOI
  12. [12]Tian F. Wu M. Deng L. Core binding factor beta (Cbfβ) controls the balance of chondrocyte proliferation and differentiation by upregulating Indian hedgehog (Ihh) expression and inhibiting parathyroid hormone-related protein receptor (PPR) expression in postnatal cartilage and bone formation Journal of Bone and Mineral Research 2014 29 7 1564 1574 10.1002/jbmr.2275 2-s2.0-84903291612 24821091 PMC4644666 · DOI
  13. [13]Skalska L. Stojnic R. Li J. Chromatin signatures at Notch-regulated enhancers reveal large-scale changes in H3K56ac upon activation The EMBO Journal 2015 34 14 1889 1904 10.15252/embj.201489923 2-s2.0-84948564302 26069324 PMC4547894 · DOI
  14. [14]Huang H. Woo A. J. Waldon Z. A Src family kinase–Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation Genes & Development 2012 26 14 1587 1601 10.1101/gad.192054.112 2-s2.0-84864019022 22759635 PMC3404386 · DOI
  15. [15]Akech J. Wixted J. J. Bedard K. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions Oncogene 2010 29 6 811 821 10.1038/onc.2009.389 2-s2.0-76849112495 19915614 PMC2820596 · DOI
  16. [16]Li X.-Q. Du X. Li D.-M. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGFβ signaling pathway Cancer Research 2015 75 16 3302 3313 10.1158/0008-5472.CAN-15-0240 2-s2.0-84942892113 26060017 · DOI
  17. [17]Ries J. Baran C. Wehrhan F. Prognostic significance of altered miRNA expression in whole blood of OSCC patients Oncology Reports 2017 37 6 3467 3474 10.3892/or.2017.5639 2-s2.0-85019580388 28498442 · DOI
  18. [18]Pedersen N. J. Jensen D. H. Lelkaitis G. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma Oral Oncology 2018 83 46 52 10.1016/j.oraloncology.2018.05.020 2-s2.0-85048273865 30098778 · DOI
  19. [19]Chen F. Qi S. Zhang X. Wu J. Yang X. Wang R. miR-23a-3p suppresses cell proliferation in oral squamous cell carcinomas by targeting FGF2 and correlates with a better prognosis: miR-23a-3p inhibits OSCC growth by targeting FGF2 Pathology-Research and Practice 2019 215 4 660 667 10.1016/j.prp.2018.12.021 2-s2.0-85059228315 30606659 · DOI
  20. [20]Dai Y. Zheng C. Li H. Inhibition of miR-23a-3p promotes osteoblast proliferation and differentiation Journal of Cellular Biochemistry 2019 1 12 31691358
  21. [21]Ma M. Dai J. Tang H. MicroRNA-23a-3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways Theranostics 2019 9 4 945 960 10.7150/thno.30516 2-s2.0-85062853542 30867808 PMC6401396 · DOI
  22. [22]Jahid S. Sun J. Edwards R. A. miR-23a promotes the transition from indolent to invasive colorectal cancer Cancer Discovery 2012 2 6 540 553 10.1158/2159-8290.CD-11-0267 2-s2.0-84866330452 22628407 PMC3651884 · DOI
  23. [23]Zhu L. Jin L. Jiang R. Correlations between miRNAs and TGF-β1 in tumor microenvironment of esophageal squamous cell cancer Chinese Journal of Cellular and Molecular Immunology 2013 29 5 524 528 23643275
  24. [24]Buo A. M. Tomlinson R. E. Eidelman E. R. Chason M. Stains J. P. Connexin43 and Runx2 interact to affect cortical bone geometry, skeletal development, and osteoblast and osteoclast function Journal of Bone and Mineral Research 2017 32 8 1727 1738 10.1002/jbmr.3152 2-s2.0-85019934320 28419546 PMC5550348 · DOI
  25. [25]Vishal M. Swetha R. Thejaswini G. Arumugam B. Selvamurugan N. Role of Runx2 in breast cancer-mediated bone metastasis International Journal of Biological Macromolecules 2017 99 608 614 10.1016/j.ijbiomac.2017.03.021 2-s2.0-85014879012 28268169 · DOI
  26. [26]Tandon M. Chen Z. Othman A. Pratap J. Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis Oncogene 2016 35 36 4730 4740 10.1038/onc.2015.518 2-s2.0-84955584237 26804175 · DOI
  27. [27]Owens T. W. Rogers R. L. Best S. A. Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer Cancer Research 2014 74 18 5277 5286 10.1158/0008-5472.CAN-14-0053 2-s2.0-84907494635 25056120 PMC4178131 · DOI
  28. [28]Gokulnath M. Swetha R. Thejaswini G. Shilpa P. Selvamurugan N. Transforming growth factor-β1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metalloproteinase-13 gene in human breast cancer cells International Journal of Biological Macromolecules 2017 94, Part A 370 377 10.1016/j.ijbiomac.2016.10.026 2-s2.0-84994779481 27751807 · DOI
  29. [29]Arumugam B. Vairamani M. Partridge N. C. Selvamurugan N. Characterization of Runx2 phosphorylation sites required for TGF-β1-mediated stimulation of matrix metalloproteinase-13 expression in osteoblastic cells Journal of Cellular Physiology 2018 233 2 1082 1094 10.1002/jcp.25964 2-s2.0-85019929722 28419442 · DOI
  30. [30]Lu H. Jiang T. Ren K. RUNX2 plays an oncogenic role in esophageal carcinoma by activating the PI3K/AKT and ERK signaling pathways Cellular Physiology and Biochemistry 2018 49 1 217 225 10.1159/000492872 2-s2.0-85052912468 30138923 · DOI

Authors
Ma, Y., Gao, J., & Guo, H.
Affiliations
Tianjin Third Central Hospital (CN)
Corresponding author
Ma, Yu
ORCID
Venue
Journal of Oncology
Publisher
Wiley
Published
2022-03-18
Volume
2022
Pages
1-11
ISSN
  • 1687-8450 (ISSN-L)
  • 1687-8469
DOI
10.1155/2022/8719542
PMC
PMC8956426
OpenAlex
W4221028174
Cited by
16
References
30
Citations by year
2026: 2 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 2
FWCI
1.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
miR-23a-3p, Runx2, oral squamous cell carcinoma, tumor suppression, cell proliferation, metastasis, PTEN, PI3K/Akt signaling, microRNA target regulation, CAL-27 cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review